Evaluation of Bupropion and Venlafaxine in Children with ADHD

A systematic review of evidence-based interventions for child and adolescent mental health problems in low- and middle-income countries

“…Over two-thirds of studies (n = 85; 79%) were randomised clinical trials (RCT) [23,[27][28][29][30][31][32][33][34][35][36][39][40][41][43][44][45][46]48 Detailed distribution of studies according to key variables is provided as Supplemental Table S1 (Appendix 2).…”

“…The most common comparator was no intervention (n = 43; 40.2%) [10,[25][26][27]29,[36][37][38]42,46,51,53,56,66,69,73,75,[89][90][91][92][93]96,97,[100][101][102][103]105,107,110,[112][113][114][116][117][118][119]121,124,126,128]. In over a quarter of studies (n = 28; 26.2%), participants in control groups received pharmacological interventions [28,30,31,34,35,41,44,45,48,...…”

“…Interventions were mostly delivered in one-to-one configuration (n = 58; 54.2%) [10,25,[28][29][30][31][33][34][35][36][37][38][39][40][41][43][44][45][46]48,[50][51][52][57][58][59][60][61][62][63][64][65][66][67][68][69]72,74,[77][78][79][80][81]84,85,87,88,94,95,98,99,104,…”

“…A variety of other delivery agents also delivered interventions, for example, other mental health professionals (n = 6; 5.6%) [36,42,49,86,88,124], teachers (n = 9; 8.4%) [89,90,93,94,98,106,112,116,118] and lay people (n = 9; 8.4%) [78,92,96,102,104,114,122,125,126]. Over one-third of studies (n = 42; 39.2%) did not report or did not specify by whom interventions were delivered [10,24,25,29,34,35,37,40,41,[43][44][45]48,50,52,54,58,60,[62][63][64][65]68,72,74,…”

Evaluation of a Potential Metabolism-Mediated Drug-Drug Interaction Between Atomoxetine and Bupropion in Healthy Volunteers

“…As it is devoid of abuse potential, atomoxetine is regarded as an appropriate alternative to the drugs that are misused (17). Bupropion is primarily acknowledged as an antidepressant and a smoking cessation agent, but also demonstrated its effectiveness for the treatment of ADHD in children and adults, although it is not approved for this indication (18)(19)(20). These pharmacological agents are not only linked to the same isoenzyme, as atomoxetine is a substrate (6), while bupropion is an enzymatic inhibitor of CYP2D6 (13), but, equally important, their association in clinical circumstances can be taken into consideration.…”